Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Jul;47(7):2376-9.
doi: 10.1128/AAC.47.7.2376-2379.2003.

The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates

Karidia Diallo  1 , Bluma Brenner, Maureen Oliveira, Daniela Moisi, Mervi Detorio, Matthias Götte, Mark A Wainberg
Affiliations

The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates

Karidia Diallo et al. Antimicrob Agents Chemother. 2003 Jul.

Abstract

The M184V substitution in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), encoding high-level resistance to lamivudine (3TC), results in decreased HIV-1 replicative capacity, diminished RT processivity, and increased RT fidelity in biochemical assays. We assessed the effect of M184V on the development of resistance to the nonnucleoside RT inhibitors efavirenz (EFV) and nevirapine, and to the protease inhibitor amprenavir (APV) in tissue culture. Genotypic analysis revealed differences in EFV resistance-conferring mutations in subtype B (K103N) versus subtype C (V106 M), and the appearance of both was significantly delayed in the M184V-containing variants compared with the wild type (WT). Similarly, there was a marked delay in the emergence of mutations associated with APV resistance (I54 M/L/V) in subtype B viruses harboring M184V compared with paired WT viral isolates.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Selection of resistance to drugs in tissue culture. (A) Stepwise progression of EFV concentrations and development of resistance in a paired experiment involving the WT and M184V-containing 4246 clinical isolates of subtype B origin. (B) Selection of resistance to EFV in WT and M184V-containing clinical isolates of subtype C origin. Concentrations of EFV are expressed as changes in mean IC50 values (n-fold). Arrows indicate time to first appearance of V106 M. Values represent the mean ± standard error of the mean (n = 6 and 2 for WT and M184V isolates, respectively). (C) Selection of resistance to APV in WT and M184V-containing clinical isolates of subtype C origin. Concentrations of APV are expressed as changes in mean IC50 values (n-fold). Arrows indicate time to first appearance of the I54L mutation.
FIG. 1.
FIG. 1.
Selection of resistance to drugs in tissue culture. (A) Stepwise progression of EFV concentrations and development of resistance in a paired experiment involving the WT and M184V-containing 4246 clinical isolates of subtype B origin. (B) Selection of resistance to EFV in WT and M184V-containing clinical isolates of subtype C origin. Concentrations of EFV are expressed as changes in mean IC50 values (n-fold). Arrows indicate time to first appearance of V106 M. Values represent the mean ± standard error of the mean (n = 6 and 2 for WT and M184V isolates, respectively). (C) Selection of resistance to APV in WT and M184V-containing clinical isolates of subtype C origin. Concentrations of APV are expressed as changes in mean IC50 values (n-fold). Arrows indicate time to first appearance of the I54L mutation.
See this image and copyright information in PMC

References

    1. Back, N. K. T., M. Nijhuis, W. Keulen, C. A. B. Boucher, B. B. O. Essnik, A. B. P. van Kuilenburg, A. H. van Gennip, and B. Berkhout. 1996. Reduced replication of 3TC-resistant HIV-l variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040-4049. - PMC - PubMed
    1. Boucher, C. A. B., N. Cammack, P. Schipper, R. Schuurman, P. L. Rouse, and J. M. Cameron. 1993. High level resistance to (−) enantiomeric 2′-deoxy-3′-thiacytidine (3TC) in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234. - PMC - PubMed
    1. Brenner, B. G., J. P. Routy, M. Petrella, D. Moisi, M. Oliveira, M. Deterio, B. Spira, V. Essabag, B. Conway, R. Lalonde, R. P. Sekaly, and M. A. Wainberg. 2002. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J. Virol. 76:1753-1761. - PMC - PubMed
    1. Brenner, B. G., D. Turner, M. Oliveira., D. Moisi, M. Detorio, M. Carobene, R. G. Marlink, J. Schapiro, M. Roger, and M. A. Wainberg. 2003. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 17:F1-F5. - PubMed
    1. Eron, J. J., S. L. Benoit, J. Jemsek, R. D. MacArthur, J. Santana, J. B. Quinn, D. R. Kuritzkes, M. A. Fallon, and M. Rubin. 1995. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N. Engl. J. Med. 333:1662-1669. - PubMed

Publication types

LinkOut - more resources